These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 25074318

  • 1. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H.
    Cardiovasc Diabetol; 2014 Jul 30; 13():110. PubMed ID: 25074318
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K, SUCCESS Study Group.
    Diabetes Obes Metab; 2014 Aug 30; 16(8):761-5. PubMed ID: 24447683
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
    Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T.
    Transl Res; 2012 Jan 30; 159(1):25-31. PubMed ID: 22153807
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 30; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.
    Diabetes Obes Metab; 2010 Apr 30; 12(4):323-33. PubMed ID: 20380653
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.
    Endocr Pract; 2013 Apr 30; 19(1):19-28. PubMed ID: 23186950
    [Abstract] [Full Text] [Related]

  • 14. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T, Pyon EY.
    Clin Ther; 2007 Dec 30; 29(12):2614-34. PubMed ID: 18201579
    [Abstract] [Full Text] [Related]

  • 15. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
    Hirata T, Inukai K, Morimoto J, Katayama S, Ishida H.
    Prim Care Diabetes; 2014 Oct 30; 8(3):265-70. PubMed ID: 24530100
    [Abstract] [Full Text] [Related]

  • 16. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B.
    Drugs Today (Barc); 2007 Oct 30; 43(10):681-9. PubMed ID: 17987221
    [Abstract] [Full Text] [Related]

  • 17. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
    Plosker GL.
    Drugs; 2014 Feb 30; 74(2):223-42. PubMed ID: 24407560
    [Abstract] [Full Text] [Related]

  • 18. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B.
    Drugs Today (Barc); 2007 Jan 30; 43(1):13-25. PubMed ID: 17315049
    [Abstract] [Full Text] [Related]

  • 19. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H.
    Circ J; 2013 Jan 30; 77(5):1337-44. PubMed ID: 23386232
    [Abstract] [Full Text] [Related]

  • 20. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.